Outcomes Following Phacoemulsification With 1.8 & 2.2mm Incision:

Status Unknown status

Clinical Trial Summary

Cataract surgical techniques have significantly changed in recent years with the widespread adoption of smaller and smaller clear corneal incisions for phacoemulsification. Microincision surgery has many advantages, including reduced surgically induced astigmatism, faster visual recovery, and reduced intra and postoperative inflammation. Curently, microcoaxial phacoemulsification is being performed through 1.8 as well as 2.2 mm incisions. However, there is still a debate as to which is the best absolute incision size for microcoaxial cataract surgery.

The aim of this study is to evaluate incision stability following microcoaxial phacoemulsification performed through 1.8 and 2.2 mm systems, as well as compare intraoperative performance and postoperative outcomes following microcoaxial phacoemulsification performed through these two incision sizes.

Clinical Trial Description

Cataract surgical techniques have significantly changed in recent years with the widespread adoption of smaller and smaller clear corneal incisions for phacoemulsification. Microincision surgery has many advantages, including reduced surgically induced astigmatism, faster visual recovery, and reduced intra and postoperative inflammation. In the recent times, microcoaxial phacoemulsification has gained popularity. The main advantage of this newer technique is that it uses the same methods as the conventional method but with smaller incisions. Curently, microcoaxial phacoemulsification is being performed through 1.8 as well as 2.2 mm incisions. However, there is still a debate as to which is the best absolute incision size for microcoaxial cataract surgery.

The aim of this study is to evaluate incision stability following microcoaxial phacoemulsification performed through 1.8 and 2.2 mm systems, as well as compare intraoperative performance and postoperative outcomes following microcoaxial phacoemulsification performed through these two incision sizes. ;

Study Design

Related Conditions & MeSH terms

Cataract

Clinical Trial Details

NCT number	NCT01385878
Study type	Interventional
Source	Iladevi Cataract and IOL Research Center
Contact	Abhay R Vasavada, MS,FRCS
Phone	91-79-27490909
Email	icirc@abhayvasavada.com
Status	Unknown status
Phase	N/A
Start date	January 2011
Completion date	December 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04685538` - Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification.	Phase 3
Recruiting	`NCT06060041` - IC-8 Apthera IOL New Enrollment Post Approval Study
Recruiting	`NCT05518539` - Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens
Recruiting	`NCT05271942` - Tilt and Tumble vs Divide and Conquer - a Unique Comparison of the Two Cataract Surgery Methods	N/A
Active, not recruiting	`NCT04778501` - PMCF Study on Monofocal Toric IOL (PODEYE TORIC) in Asia	N/A
Completed	`NCT05062564` - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye	N/A
Completed	`NCT03751033` - Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings	N/A
Completed	`NCT02529488` - Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00	N/A
Completed	`NCT04539548` - A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract	Phase 3
Completed	`NCT03740659` - Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery	Phase 2
Completed	`NCT03494257` - Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification	N/A
Completed	`NCT05119127` - Rotational Stability of Acrysof IQ Vivity Extended Vision Toric IOL and Refractive Visual Outcome.	N/A
Active, not recruiting	`NCT04271709` - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)	N/A
Recruiting	`NCT03713268` - Intraoperative OCT Guidance of Intraocular Surgery II
Completed	`NCT03739528` - Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery	Phase 3
Completed	`NCT02888210` - A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery	Phase 3
Completed	`NCT03356847` - Evaluation of the Rotational Stability of the Monofocal SISA Implant Following Cataract Surgery	N/A
Completed	`NCT04332640` - Clinical Evaluation of the Next Generation Phaco System	N/A
Recruiting	`NCT03638726` - Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification	Phase 4
Completed	`NCT03050697` - Evaluation of the Safety and Performance of the HARMONI® Toric Lens	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Outcomes Following Phacoemulsification With 1.8 & 2.2mm Incision: Randomized Clinical Trial

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms